Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 30:1:264-268.
doi: 10.1016/j.ymgmr.2014.06.001. eCollection 2014.

Disease-associated marked hyperalphalipoproteinemia

Ken-Ichi Hirano  1 , Hironori Nagasaka  2 , Kazuhiro Kobayashi  3 , Satoshi Yamaguchi  1 , Akira Suzuki  1 , Tatsushi Toda  3 , Manabu Doyu  4
Affiliations

Disease-associated marked hyperalphalipoproteinemia

Ken-Ichi Hirano et al. Mol Genet Metab Rep. .

Abstract

Marked hyperalphalipoproteinemia (HAL) is a heterogeneous syndrome. To clarify the pathophysiological significance of HAL, we compared clinical profiles between marked HAL subjects with and without cholesteryl ester transfer protein (CETP) deficiency. CETP deficiency was associated with cardiovascular diseases and strokes in the HAL population, particularly in female. HAL women without CETP deficiency tended to have higher prevalence with cancer history. HAL may not always be a longevity marker, but be sometimes accompanied with pathological conditions.

Keywords: Atherosclerosis; Cardiovascular disease; Cholesteryl ester transfer protein deficiency; High density lipoprotein; Hyperalphalipoproteinemia; Stroke.

PubMed Disclaimer

References

    1. Matsuzawa Y., Yamashita S., Kameda K., Kubo M., Tarui S., Hara I. Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report. Atherosclerosis. 1984;53:207–212. ( http://www.ncbi.nlm.nih.gov/pubmed/6517975) - PubMed
    1. Koizumi J., Mabuchi H., Yoshimura A., Michishita I., Takeda M., Itoh H., Sakai Y., Sakai T., Ueda K., Takeda R. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985;58:175–186. ( http://www.ncbi.nlm.nih.gov/pubmed/3937535) - PubMed
    1. Yamashita S., Matsuzawa Y., Okazaki M., Kako H., Yasugi T., Akioka H., Hirano K., Tarui S. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis. 1988;70:7–12. ( http://www.ncbi.nlm.nih.gov/pubmed/3355618) - PubMed
    1. Tall A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 1993;34:1255–1274. ( http://www.ncbi.nlm.nih.gov/pubmed/8409761) - PubMed
    1. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., Maruhama Y., Mabuchi H., Tall A.R. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 1990;323:1234–1238. - PubMed

LinkOut - more resources